Biomea Fusion opened lower at $0.61, compared with its previous close of $0.61. In the last trading session, the stock traded between $0.57 and $0.63. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Biomea Fusion is now worth
$ 4.83
Resulting in a loss of
$ 95.17 (95.17%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.04 (-7.02%)
Day High
$0.63
Day Low
$0.57
Day Open
$0.61
Prev Close
$0.61
Volume
7,47,957
1W Return
-7.19%
1M Return
-58.39%
3M Return
-56.14%
6M Return
-63.82%
1Y Return
-59.43%
Fundamentals
Market Cap ($ Mn)
41
PE Ratio
-
PB Ratio
10.33
PEG Ratio
-
ROE
-201.96%
ROCE
-134.75%
EPS (TTM)
$-0.11
Investment Returns
1 Week
-7.19%
1 Month
-58.39%
3 Months
-56.14%
6 Months
-63.82%
9 Months
-56.64%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
11Nov
Biomea Fusion Q3 Results: Loss per share narrows 66.67% YoY
Reported loss per share of $(0.09) for Q3. Beat analyst consensus estimate of $(0.21) by 57.14%. Improved 66.67% from prior year loss of $(0.27).
2 days ago
14Oct
Biomea Fusion details BMF-650 safety profile in Phase 1 update
Biomea Fusion reported preliminary Phase 1 results for oral GLP-1 drug BMF-650. No severe or serious adverse events or liver enzyme increases were observed. Nausea occurred in 17.5% and vomiting in 7.5% across active dose cohorts. Mean weight reduction reached 6.1% in the highest dosing confined cohort. Company plans longer-term toxicology studies and strategic partnership discussions.
1mo ago
23Sep
Biomea Fusion scraps equity offering, delays study data
Biomea Fusion terminated its proposed public offering citing unfavorable market conditions. Phase I topline results for BMF-650 delayed to October 2026 from Q3FY26. Shares fell 19.12% to $1.37 as investors reacted to the financing pause. No securities were sold; Konik Capital Partners was the sole underwriter.
1mo ago
23Sep
Biomea Fusion pushes BMF-650 obesity trial data to October
Biomea Fusion delays topline data from Phase 1 obesity trial of BMF-650. Data release moved from Q3 to October 2026. Update confirmed via SEC filing dated September 22, 2026.
1mo ago
25Aug
Biomea Fusion shares up 16% as COVALENT-211 enrollment completes
Biomea Fusion shares rose 16.06% to $1.59 on Monday. Company completed enrollment of 64 participants in COVALENT-211 Phase II trial. Topline primary endpoint data expected in first quarter of 2027. Companion trial COVALENT-212 enrollment ongoing with results due Q2 2027. Earlier data showed up to 1.8% placebo-adjusted HbA1c reduction at Week 52.
Biomea Fusion delivered better-than-expected second-quarter results with an EPS of $(0.12), beating the $(0.22) estimate by 45.45%. The quarter saw a 76.47% improvement in losses compared to the prior year's $(0.51) per share, indicating a positive trend in financial performance despite ongoing net losses.
